Skip to main content
Top

2013 | OriginalPaper | Chapter

Why Is This Subgroup Different from All Other Subgroups? Thoughts on Regional Differences in Randomized Clinical Trials

Author : Janet Wittes

Published in: Proceedings of the Fourth Seattle Symposium in Biostatistics: Clinical Trials

Publisher: Springer New York

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

Many Phase 3 randomized clinical trials are currently being conducted multinationally with too few participants from any individual country to allow reliable inference about the beneficial or harmful effects of the tested product using data from that country alone. Instead, the conclusions for a given country will come from the totality of the data. Insofar as “country” is just another subgroup defined by baseline variables, this strategy is defensible. On the other hand, in cases where “country” stands as a surrogate for country-specific variables that importantly influence the benefits and harms of an intervention, inferring from the study population at large to specific countries may be less appropriate. Such variables may include the nature of the disease being studied, the country-specific standard of care, the patterns of safety reporting, and the extent of adherence to study protocol. This paper presents four examples of studies where the observed treatment effect in the USA differed considerably from the effect observed elsewhere. It argues that the problem is in some sense intractable because a study large enough to provide precise estimates of effect sizes within specific countries would likely be infeasible. Instead, although the paper recommends generally applying the overall result to the participating countries, it provides suggestions for strategies in the design and analysis phase to mitigate potential inferential ambiguities.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Literature
1.
go back to reference Simon R (1980) Patient heterogeneity in clinical trials. Cancer Treat Rep 64(2–3):405–410 Simon R (1980) Patient heterogeneity in clinical trials. Cancer Treat Rep 64(2–3):405–410
2.
go back to reference Simon R (1982) Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 14:473–482CrossRef Simon R (1982) Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 14:473–482CrossRef
4.
go back to reference Oxman A, Guyatt G (1992) A consumer’s guide to subgroup analysis. Ann Intern Med 116:78–84 Oxman A, Guyatt G (1992) A consumer’s guide to subgroup analysis. Ann Intern Med 116:78–84
5.
go back to reference Lagakos S (2006) The challenge of subgroup analyses – reporting without distorting. N Engl J Med 354(16):1667–1669CrossRef Lagakos S (2006) The challenge of subgroup analyses – reporting without distorting. N Engl J Med 354(16):1667–1669CrossRef
6.
7.
go back to reference Yusuf S, Wittes J, Probstfield J, Tyroler H (1991) Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J Am Med Assoc 266(1):93–98CrossRef Yusuf S, Wittes J, Probstfield J, Tyroler H (1991) Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J Am Med Assoc 266(1):93–98CrossRef
8.
go back to reference The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 265(24):3255–3264CrossRef The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 265(24):3255–3264CrossRef
9.
go back to reference Quan H, Li M, Chen J et al (2010) Assessment of consistency of treatment effects in multiregional clinical trials. Drug Inf J 44:616–632CrossRef Quan H, Li M, Chen J et al (2010) Assessment of consistency of treatment effects in multiregional clinical trials. Drug Inf J 44:616–632CrossRef
10.
go back to reference Kim E, Carrigan T, Menon V (2011) International participation in cardiovascular randomized controlled trials. J Am Coll Cardiol 58:671–676CrossRef Kim E, Carrigan T, Menon V (2011) International participation in cardiovascular randomized controlled trials. J Am Coll Cardiol 58:671–676CrossRef
11.
go back to reference Bartlett D, Steele J (2011) Deadly medicine. Vanity Fair, January 2011 Bartlett D, Steele J (2011) Deadly medicine. Vanity Fair, January 2011
13.
go back to reference Luo X, Shih W, Ouyang S, DeLap R (2010) An optimal adaptive design to address local regulations in global clinical trials. Pharm Stat 9:179–189CrossRef Luo X, Shih W, Ouyang S, DeLap R (2010) An optimal adaptive design to address local regulations in global clinical trials. Pharm Stat 9:179–189CrossRef
14.
go back to reference Nandakumar A, Anantha N, Venugopal T (1995) Incidence, mortality, and survival in cancer of the cervix in Bangalore, India. Br J Cancer 71(6):1348–1352CrossRef Nandakumar A, Anantha N, Venugopal T (1995) Incidence, mortality, and survival in cancer of the cervix in Bangalore, India. Br J Cancer 71(6):1348–1352CrossRef
15.
go back to reference GlaxoSmithKline (2010) Package insert for Relenza GlaxoSmithKline (2010) Package insert for Relenza
16.
go back to reference International Steering Committee on behalf of the MERIT-HF Study Group (1997) Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 80(Suppl 9B):54J–58J International Steering Committee on behalf of the MERIT-HF Study Group (1997) Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 80(Suppl 9B):54J–58J
17.
go back to reference MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007CrossRef MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007CrossRef
18.
go back to reference FDA (2000) Statistical review and evaluation (Amendment 1). NDA 19,962. May 30, 2000 FDA (2000) Statistical review and evaluation (Amendment 1). NDA 19,962. May 30, 2000
19.
20.
go back to reference FDA memo as quoted by Moyé L (2000) Multiple Analyses in Clinical Trials. Springer, New York FDA memo as quoted by Moyé L (2000) Multiple Analyses in Clinical Trials. Springer, New York
21.
go back to reference Wedel H, DeMets D, Deedwania P et al (2001) Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 142:502–511CrossRef Wedel H, DeMets D, Deedwania P et al (2001) Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 142:502–511CrossRef
22.
go back to reference Wallentin L, Becker R, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary symptoms. N Engl J Med 361(11):1045–1057CrossRef Wallentin L, Becker R, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary symptoms. N Engl J Med 361(11):1045–1057CrossRef
23.
go back to reference Mahaffery KW, Wojdyla DM, Carroll K, et al (2011) Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124(5):544–554CrossRef Mahaffery KW, Wojdyla DM, Carroll K, et al (2011) Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124(5):544–554CrossRef
24.
go back to reference Fiorentino R, Zhang J (2010) NDA 22–433 Brinlinta (ticagrelor) Efficacy Review the Cardio-Renal Advisory Committee, July 28, 2010 Fiorentino R, Zhang J (2010) NDA 22–433 Brinlinta (ticagrelor) Efficacy Review the Cardio-Renal Advisory Committee, July 28, 2010
25.
go back to reference AstraZeneca (2011) Package insert for Brinlinta (ticagrelor) AstraZeneca (2011) Package insert for Brinlinta (ticagrelor)
26.
go back to reference StatXact 9 [computer program]. Cytel, Cambridge, MA StatXact 9 [computer program]. Cytel, Cambridge, MA
27.
go back to reference Human Genome Sciences (2010) Package insert for Benlysta Human Genome Sciences (2010) Package insert for Benlysta
28.
go back to reference Marschner IC (2010) Regional differences in multinational clinical trials: anticipating chance variation. Clin Trials 7(2):147–156CrossRef Marschner IC (2010) Regional differences in multinational clinical trials: anticipating chance variation. Clin Trials 7(2):147–156CrossRef
29.
go back to reference Lan K, Wittes J (2012) Some thoughts on sample size: a Bayesian-frequentist hybrid approach. Clin Trials. 1740774512453784, first published on August 3, 2012 as doi:10.1177/1740774512453784 Lan K, Wittes J (2012) Some thoughts on sample size: a Bayesian-frequentist hybrid approach. Clin Trials. 1740774512453784, first published on August 3, 2012 as doi:10.​1177/​1740774512453784​
30.
go back to reference Morrison T (2010) Lesson from an Alzheimer-drug failure: beware Russian clinical trial data (March 5, 2010). BNET, 2010 Morrison T (2010) Lesson from an Alzheimer-drug failure: beware Russian clinical trial data (March 5, 2010). BNET, 2010
31.
go back to reference Quan H, Li M, Chen J et al (2010) Assessment of treatment effects in multiregional clinical trials. Drug Inf J 44:617–632CrossRef Quan H, Li M, Chen J et al (2010) Assessment of treatment effects in multiregional clinical trials. Drug Inf J 44:617–632CrossRef
Metadata
Title
Why Is This Subgroup Different from All Other Subgroups? Thoughts on Regional Differences in Randomized Clinical Trials
Author
Janet Wittes
Copyright Year
2013
Publisher
Springer New York
DOI
https://doi.org/10.1007/978-1-4614-5245-4_7

Premium Partner